Bradykinin Receptor B1 (BDKRB1) Antibody

Background

Bradykinin Receptor B1 (BDKRB1) is an inducible GPCR primarily expressed during inflammatory responses and tissue injury. Unlike the constitutively expressed B2 receptor, B1 is induced by pro-inflammatory cytokines, such as IL-1β and TNF-α, in response to chronic inflammation, trauma, or infection. BDKRB1 binds des-Arg9-bradykinin, a bradykinin metabolite, and mediates pro-inflammatory effects, including pain sensitization, vasodilation, and vascular permeability. This receptor plays a pivotal role in chronic pain conditions, such as neuropathic pain and inflammatory hyperalgesia, by sensitizing sensory neurons and enhancing pain signaling. BDKRB1 also contributes to angiogenesis and leukocyte recruitment, facilitating immune responses during infection and injury. In the cardiovascular system, B1 activation is associated with hypertension, vascular remodeling, and endothelial dysfunction. Dysregulation of BDKRB1 signaling is linked to conditions like diabetic complications, chronic inflammatory diseases, and certain cancers, where it can promote tumor growth and metastasis. Targeting BDKRB1 with antagonists has shown promise in preclinical models for managing chronic pain, inflammation, and vascular disorders, making it an emerging target for therapeutic development.